title: Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia.
abstract: Allogeneic hematopoietic transplantation, an effective treatment for acute myeloid leukemia (AML), was originally developed as a means of delivering high-dose myeloablative chemotherapy or radiation. The transplant itself allowed stem cells to restore normal hematopoiesis and immunity. Yet older people were denied this treatment because the myeloablative therapy has considerable toxicity. More recently, reduced-intensity conditioning has been used, allowing older or medically infirm patients to receive a transplant. This review explores the feasibility of transplant as a standard of care for older patients.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas-MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: rchampli@mdanderson.org.
authors.forename: Richard
authors.initials: R
authors.lastname: Champlin
mesh_terms: D000367:Age Factors; D000368:Aged; D005720:Gamma Rays; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D059039:Standard of Care; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists
keywords: AML; acute myeloid leukemia; allogeneic; elderly; hematopoietic transplantation; nonmyeloablative; reduced intensity conditioning; stem cell transplantation